SWOG 80702: Overview of Study Design, Efficacy End Points, and Patient Characteristics

Panelists discuss how SWOG 80702, a large-scale randomized clinical trial, employed a robust factorial design with clearly defined efficacy end points, including disease-free and overall survival, while enrolling a diverse patient population with stage III colon cancer to evaluate optimal adjuvant therapy duration and the impact of celecoxib.

EP: 1.The Role of ctDNA in CRC

EP: 2.BESPOKE: Study Design, Efficacy End Points, and Methods

EP: 3.Overview of BESPOKE Patient Characteristics

EP: 4.BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

EP: 5.BESPOKE: ctDNA Clearance During and After ACT

EP: 6.Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy

Now Viewing

EP: 7.SWOG 80702: Overview of Study Design, Efficacy End Points, and Patient Characteristics

EP: 8.SWOG 80702: Impressions on the Efficacy Data

EP: 9.Potential Role of Tumor-Informed ctDNA in CRC

EP: 10.Importance of Patient-Centric Approach and Patient Education of ctDNA Testing in CRC and Looking Ahead

EP: 11.The Role of ctDNA Testing in Colorectal Cancer Management: Exploring Its Use Alongside Imaging in Challenging Cases

EP: 12.Research Considerations for ctDNA Testing in Colorectal Cancer

Recent Videos